Cargando…

Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study

BACKGROUND: Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously reported. METHODS: We conducted a cohort study using linked Hospital Episodes S...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratib, Sonia, Walker, Alex J., Card, Tim R., Grainge, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962547/
https://www.ncbi.nlm.nih.gov/pubmed/27461026
http://dx.doi.org/10.1186/s13045-016-0291-0
_version_ 1782444856330682368
author Ratib, Sonia
Walker, Alex J.
Card, Tim R.
Grainge, Matthew J.
author_facet Ratib, Sonia
Walker, Alex J.
Card, Tim R.
Grainge, Matthew J.
author_sort Ratib, Sonia
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously reported. METHODS: We conducted a cohort study using linked Hospital Episodes Statistics and Office for National Statistics mortality data. We determined the risk of VTE separately for 24 cancer sites following first hospitalisation for cancer (index date) and how this varied by age, proximity from hospital admission, administration of chemotherapy and calendar time. RESULTS: Between 1998 and 2012, 3,558,660 patients were hospitalised for cancer. The cancer sites with the highest risk of VTE during initial hospitalisation for cancer were pancreatic (4.9 %), ovarian (4 %) and liver (3.8 %). The three cancer sites with the highest risk of first VTE event within 6 months from discharge were pancreatic (3.7 %), oesophagus (3 %) and stomach (2.8 %). For most cancers, the risk of VTE within 6 months from discharge was higher amongst patients who underwent chemotherapy compared to those who did not. The impact of age on risk of VTE varied considerably between cancer sites. CONCLUSIONS: The risk of VTE amongst patients hospitalised for cancer varies greatly by cancer site, age, proximity from hospital admission, and chemotherapy administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0291-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4962547
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49625472016-07-28 Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study Ratib, Sonia Walker, Alex J. Card, Tim R. Grainge, Matthew J. J Hematol Oncol Research BACKGROUND: Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously reported. METHODS: We conducted a cohort study using linked Hospital Episodes Statistics and Office for National Statistics mortality data. We determined the risk of VTE separately for 24 cancer sites following first hospitalisation for cancer (index date) and how this varied by age, proximity from hospital admission, administration of chemotherapy and calendar time. RESULTS: Between 1998 and 2012, 3,558,660 patients were hospitalised for cancer. The cancer sites with the highest risk of VTE during initial hospitalisation for cancer were pancreatic (4.9 %), ovarian (4 %) and liver (3.8 %). The three cancer sites with the highest risk of first VTE event within 6 months from discharge were pancreatic (3.7 %), oesophagus (3 %) and stomach (2.8 %). For most cancers, the risk of VTE within 6 months from discharge was higher amongst patients who underwent chemotherapy compared to those who did not. The impact of age on risk of VTE varied considerably between cancer sites. CONCLUSIONS: The risk of VTE amongst patients hospitalised for cancer varies greatly by cancer site, age, proximity from hospital admission, and chemotherapy administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0291-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4962547/ /pubmed/27461026 http://dx.doi.org/10.1186/s13045-016-0291-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ratib, Sonia
Walker, Alex J.
Card, Tim R.
Grainge, Matthew J.
Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title_full Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title_fullStr Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title_full_unstemmed Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title_short Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study
title_sort risk of venous thromboembolism in hospitalised cancer patients in england—a cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962547/
https://www.ncbi.nlm.nih.gov/pubmed/27461026
http://dx.doi.org/10.1186/s13045-016-0291-0
work_keys_str_mv AT ratibsonia riskofvenousthromboembolisminhospitalisedcancerpatientsinenglandacohortstudy
AT walkeralexj riskofvenousthromboembolisminhospitalisedcancerpatientsinenglandacohortstudy
AT cardtimr riskofvenousthromboembolisminhospitalisedcancerpatientsinenglandacohortstudy
AT graingematthewj riskofvenousthromboembolisminhospitalisedcancerpatientsinenglandacohortstudy